Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Tobemstomig?
Tobemstomig is a monoclonal antibody commercialized by Roche, with a leading Phase II program in Metastatic Melanoma. According to Globaldata,...
Tobemstomig by F. Hoffmann-La Roche for Metastatic Melanoma: Likelihood of Approval
Tobemstomig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Melanoma. According to GlobalData,...
Tobemstomig by F. Hoffmann-La Roche for Solid Tumor: Likelihood of Approval
Tobemstomig is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Solid Tumor. According to GlobalData,...